Lyric Bio
Palo Alto
About Lyric Bio
LYRIC BIO develops biomanufacturing platforms for human donor-sourced therapeutics. The company focuses initially on increasing availability of intravenous immunoglobulin, using bioreactors that incorporate high-resolution, laser-printed 3D tissues originating from research at Prellis Biologics. Its approach integrates cell culture systems, process design, and scalable hardware to expand throughput while maintaining product consistency. Capabilities include the design of bioreactor components, process monitoring, and quality controls aligned to plasma-derived medicines. The goal is to reduce supply shortages for essential immunoglobulin therapies and create a path to broader access for donor-based biologics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $6.6M
- Funding stage: Seed
- Last round: Seed (Dec 2025)
- Website: lyricbio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/lyric-bio-44391 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.